Exact Sciences Corp. (EXAS), a provider of cancer screening and diagnostic tests, has witnessed a significant drop in its stock value over the past year, dropping from nearly $100 to approximately $40, largely due to growing investor concerns regarding increased competition in the cancer screening market.
The company's flagship product is the Cologuard test, the first and only FDA-approved non-invasive, multitarget stool-based DNA screening test that detects DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com